指南与共识分子诊断临床免疫质量管理与危急值

COVID-19的分子、血清学与生化诊断及监测:IFCC工作组最新证据评估

Molecular, serological, and biochemical diagnosis and monitoring of COVID-19: IFCC taskforce evaluation of the latest evidence.
指南 / 共识 · Clin Chem Lab Med · 2020-01-01

IFCC COVID-19工作组综述了分子、血清学及生化检测在COVID-19诊断与监测中的最新证据与现状。文章指出分子检测快速开发但验证要求低、血清学检测缺乏同行评审数据与监管,强调实验室专业人员应稳健验证与评估这些检测以适用临床。

要点

  • 分子检测快速开发但验证要求低,临床诊断准确性存疑。
  • 血清学检测缺乏同行评审数据与监管,需实验室稳健验证。
  • 实验室专业人员应主导检测的验证与评估以指导临床使用。

核心结论

  • 分子与血清学检测的适当临床使用需实验室专业人员稳健验证和评估。

研究设计与样本

  • IFCC COVID-19工作组综述分子、血清学及生化检测在COVID-19诊断与监测中的最新证据与现状。

主要发现

  • 分子检测以空前速度开发、生产与分发,导致验证要求最低并引发临床诊断准确性担忧。
  • 血清学检测可检测SARS-CoV-2抗体,但缺乏同行评审数据与监管,且存在使用误区。

临床怎么用

  • 实验室专业人员应对分子与血清学检测进行稳健验证和评估以支持适当临床使用。

局限性

  • 分子与血清学检测缺乏同行评审数据与监管。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The global coronavirus disease 2019 (COVID-19) has presented major challenges for clinical laboratories, from initial diagnosis to patient monitoring and treatment. Initial response to this pandemic involved the development, production, and distribution of diagnostic molecular assays at an unprecedented rate, leading to minimal validation requirements and concerns regarding their diagnostic accuracy in clinical settings. In addition to molecular testing, serological assays to detect antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are now becoming available from numerous diagnostic manufacturers. In both cases, the lack of peer-reviewed data and regulatory oversight, combined with general misconceptions regarding their appropriate use, have highlighted the importance of laboratory professionals in robustly validating and evaluating these assays for appropriate clinical use. The International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Task Force on COVID-19 has been established to synthesize up-to-date information on the epidemiology, pathogenesis, and laboratory diagnosis and monitoring of COVID-19, as well as to develop practical recommendations on the use of molecular, serological, and biochemical tests in disease diagnosis and management. This review summarizes the latest evidence and status of molecular, serological, and biochemical testing in COVID-19 and highlights some key considerations for clinical laboratories operating to support the global fight against this ongoing pandemic. Confidently this consolidated information provides a useful resource to laboratories and a reminder of the laboratory's critical role as the world battles this unprecedented crisis.

来源:Clin Chem Lab Med,查看原文。版权归原作者所有。

引用

  1. Bohn MK, Lippi G, Horvath A, et al. Molecular, serological, and biochemical diagnosis and monitoring of COVID-19: IFCC taskforce evaluation of the latest evidence. Clin Chem Lab Med. 2020. PMID: 32459192. doi:10.1515/cclm-2020-0722

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。